Empowered Funds’s Acumen Pharmaceuticals ABOS Stock Holding History

Empowered Funds’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$192K	Buy	+86,389	New	+$223K	﹤0.01%	2275

Other funds holding ABOS

Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Knollwood Investment Advisory Hunt Valley, Maryland $1.18B AUM 37.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $33B AUM 30.04% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $36.2B AUM 20.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Empowered Funds's ABOS Position: Q3 2026 in Review

Empowered Funds opened a new position in Acumen Pharmaceuticals (ABOS) in Q3 2026: 86,389 shares worth $192K. The stake represents ﹤0.01% of the portfolio and ranks #2275 among its holdings.

67 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

Empowered Funds held 86,389 shares of Acumen Pharmaceuticals worth $192K as of Q3 2026.
Acumen Pharmaceuticals was a new Empowered Funds position in Q3 2026.
Acumen Pharmaceuticals made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2275 holding.
67 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.